Table 3.

Adverse Events and Serious Adverse Events That Occurred during the Treatment Period.

Event	Chlorthalidone (N = 81)		Placebo (N = 79)
	no. of patients with event (%)	no. of events	no. of patients with event (%)	no. of events
Adverse events
Total	74 (91)	330	68 (86)	219
Infection	6 (7)	6	10 (13)	10
Cardiovascular event	2 (2)	2	3 (4)	3
Other	42 (52)	57	39 (49)	64
Event of interest	69 (85)	265	56 (71)	142
Hypokalemia	8 (10)	10	0	0
Hypomagnesemia	19 (23)	35	13 (16)	26
Hyponatremia	9 (11)	12	6 (8)	6
Hypocalcemia	1 (1)	1	1 (1)	3
Hypercalcemia	2 (2)	3	2 (3)	3
Hyperglycemia	13 (16)	18	4 (5)	5
Hyperuricemia	16 (20)	32	7 (9)	9
Hyperkalemia	5 (6)	5	7 (9)	8
Hypernatremia	0	0	1 (1)	1
Acute gout	2 (2)	2	3 (4)	3
Syncope	2 (2)	2	1 (1)	1
Orthostatic hypotension*	8 (10)	12	5 (6)	8
Dizziness†	20 (25)	33	13 (16)	24
Asymptomatic orthostatic hypotension‡	21 (26)	39	18 (23)	33
Acute kidney injury	33 (41)	61	10 (13)	12
Serious adverse events §
Infection	2 (2)	3	1 (1)	1
Cardiovascular event	3 (4)	3	5 (6)	7
Renal event	1 (1)	1	1 (1)	1
Event of interest	3 (4)	4	0	0
Other	3 (4)	3	5 (6)	6
Total	8 (10)	14	11 (14)	15

^*Orthostatic hypotension was defined as a decrease in the standing systolic blood pressure greater than 20 mm Hg, accompanied by a feeling of dizziness or light-headedness.

^†Dizziness was recorded when the patient felt dizzy when standing from a seated position but did not have a decrease in the systolic blood pressure greater than 20 mm Hg.

^‡Asymptomatic orthostatic hypotension was defined as a decrease in the standing systolic blood pressure greater than 20 mm Hg that was not accompanied by a feeling of dizziness or light-headedness.

^§Some patients had multiple serious adverse events. The four events of interest that occurred among the three patients in the chlorthalidone group were orthostatic hypotension, acute kidney injury, hyperglycemia, and hypokalemia.